RT Journal Article
SR Electronic
T1 A nonrandomized phase 2 trial of oral thymic peptides in hospitalized patients with Covid-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.05.21267318
DO 10.1101/2021.12.05.21267318
A1 Ramos-Zaldívar, Héctor M.
A1 Reyes-Perdomo, Karla G.
A1 Espinoza-Moreno, Nelson A.
A1 Dox-Cruz, Ernesto Tomás
A1 Aguirre Urbina, Thania Camila
A1 Rivera Caballero, Astrid Yohaly
A1 Perdomo Dominguez, Eduardo Smelin
A1 Peña Calix, Sofía Guadalupe
A1 Monterroso-Reyes, Joselin Michelle
A1 Caballero Vásquez, Erick Fernando
A1 Zelaya Ortiz, Tarek Sai
A1 Rodríguez-Machado, Hilbron Eduardo
A1 Forgas Solis, Marcelo Andres
A1 Silva, Iveth Sebilla
A1 Zavala Galeano, Mauricio Edgardo
A1 Morga Alvarado, Alejandro Antonio
A1 Solís Medina, Angie María Nicolle
A1 Guerrero-Díaz, Leticia M.
A1 Jiménez-Faraj, Julia E.
A1 Perelló Santos, Caroll Alejandra
A1 Moncada Arita, Wilberg A.
A1 Valdiviezo Montufar, Darwing Fabricio
A1 Hernández Sabillón, Josué David
A1 Sorto G., Mónica L.
A1 Padilla Navarro, Xochilt Xiomara
A1 Palomo-Bermúdez, Victoria A.
A1 Alvarenga Andino, Héctor Armando
A1 Reyes Guzman, Sandra Patricia
A1 Rivera Reyes, María Haydee
A1 Medina Paz, Esdras Said
A1 Alvarado Enamorado, Joselyn Rosario
A1 Sabillón Sagastume, Yenny Mariel
A1 Mejia Rivera, Ariadna Stephanny
A1 Posas Sarmiento, Claudia Michelle
A1 Jiménez Pineda, Xenia Vanessa
A1 Hernández Puerto, Verónica Alejandra
A1 Portillo Landaverde, Josué David
A1 Sergio, Reyes S.
A1 Perdomo R., Ivin
A1 Rivera, Josué J.
A1 Mendoza Girón, Wendy Cecilia
A1 Tróchez Sabillón, Karla Melissa
A1 Katsumata Leiva, Paola Nohemy
A1 Pineda Toro, Karla Elizabeth
A1 Montes-Gambarelli, Jimena A.
A1 Flores, Cristhiam
A1 Salas-Huenuleo, Edison
A1 Andia, Marcelo E.
YR 2021
UL http://medrxiv.org/content/early/2021/12/07/2021.12.05.21267318.abstract
AB Background Coronavirus disease 2019 (Covid-19) active cases continue to demand the development of safe and effective treatments. This is the first clinical trial to evaluate the safety and efficacy of oral thymic peptides.Methods We conducted a nonrandomized phase 2 trial with a historic control group to evaluate the safety and efficacy of a daily 250-mg oral dose of thymic peptides in the treatment of hospitalized Covid-19 patients. Comparison based on standard care from registry data was performed after propensity score matching. The primary outcomes were survival, time to recovery and the number of participants with treatment-related adverse events or side effects by day 20.Results A total of 44 patients were analyzed in this study, 22 in the thymic peptides group and 22 in the standard care group. There were no deaths in the intervention group, compared to 24% mortality in standard care by day 20 (log-rank P=0.02). The Kaplan-Meier analysis showed a significantly shorter time to recovery by day 20 in the thymic peptides group as compared with standard care (median, 6 days vs. 12 days; hazard ratio for recovery, 2.75 [95% confidence interval, 1.34 to 5.62]; log-rank P=0.002). No side effects or adverse events were reported.Conclusion In patients hospitalized with Covid-19, the use of thymic peptides reported no side effects, adverse events, or deaths by day 20. When compared with registry data, a significantly shorter time to recovery and mortality reduction was measured. The Catholic University of Honduras Medical Research Group (GIMUNICAH) is working on a more extensive phase 3 trial.Trial registration ClinicalTrials.gov NCT04771013. February 25, 2021.Competing Interest StatementHéctor M. Ramos Zaldívar, Karla G. Reyes-Perdomo, and Héctor Armando Alvarenga Andino designed the modified protocol for isolation of thymic peptides, which is patent pending. Héctor M. Ramos Zaldívar receives a grant for education from the Universidad Católica de Honduras. The rest of the authors declare no competing interests.Clinical TrialClinicalTrials.gov Identifier: NCT04771013Funding StatementThe research reported was funded by the Universidad Católica de Honduras.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Catholic University of Honduras IRB in Tegucigalpa gave approval for this work. The study was approved and registered by the national regulatory entity for clinical trials, the General Directorate for Regulatory Framework Surveillance of the Ministry of Health of Honduras (DGVMN) the eighth of February of 2021; enrollment began tenth of February of 2021.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPlan to Share Individual Participant Data (IPD): Yes Plan Description: All of the individual participant data collected during the trial, after deidentification. Supporting Materials: Study Protocol Supporting Materials: Statistical Analysis Plan (SAP) Supporting Materials: Informed Consent Form (ICF) Supporting Materials: Clinical Study Report (CSR) Supporting Materials: Analytic Code Time Frame: Beginning 3 months and ending 5 years following article publication. Email addresses hramos{at}unicah.edu; hmramos{at}uc.cl Access Criteria: Investigators whose proposed use of the data has been approved by an independent review committee ("learned intermediary") identified for this purpose. For individual participant data meta-analysis.